Alzinova AB (SE:ALZ)
:ALZ
Want to see SE:ALZ full AI Analyst Report?
Top Page
Alzinova AB
(ALZ)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr0.53
▼(-35.98% Downside)
Action:Reiterated
Date:06/25/26
The score is held down primarily by weak financial performance—revenue has collapsed to effectively zero and losses/cash burn remain heavy—despite a low-debt balance sheet that reduces solvency risk. Technicals provide a mild offset with short-term momentum improving, but longer-term trend signals remain weak. Valuation is also constrained by ongoing losses (negative P/E) and no stated dividend yield.
Positive Factors
Low leverage / balance sheet strength
Very low debt-to-equity (~0.7%) reduces solvency risk and gives management flexibility. For a clinical-stage biotech this structural conservatism supports continued R&D spending, negotiating power in partnerships and lower bankruptcy risk versus highly leveraged peers.
Negative Factors
Revenue collapse
Revenue has effectively fallen to zero, indicating no commercialized products and no organic sales runway. Over months, lack of product revenue forces reliance on external financing or deals, weakening self-funding ability and increasing strategic pressure to secure partnerships or dilutive raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet strength
Very low debt-to-equity (~0.7%) reduces solvency risk and gives management flexibility. For a clinical-stage biotech this structural conservatism supports continued R&D spending, negotiating power in partnerships and lower bankruptcy risk versus highly leveraged peers.
Read all positive factors
Alzinova AB (ALZ) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr84.45M
Dividend YieldN/A
Average Volume (3M)655.64K
Price to Earnings (P/E)―
Beta (1Y)0.23
Revenue Growth-100.00%
EPS Growth11.65%
CountrySE
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding154,961,400
10 Day Avg. Volume664,473
30 Day Avg. Volume655,642
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Alzinova AB Business Overview & Revenue Model
Company Description
Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for ...
How the Company Makes Money
Alzinova’s primary source of cash inflow is typically financing rather than product revenue, as the company is in the clinical-stage biotech phase and generally does not have marketed products. Potential revenue generation pathways include: (1) Li...
Alzinova AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 30.00K | 270.00K | 16.63M | 17.32M |
| Gross Profit | 20.59M | 26.55M | 16.81M | 19.87M | 33.27M | 34.64M |
| EBITDA | -24.71M | -25.85M | -20.32M | 42.00K | -13.07M | -7.52M |
| Net Income | -26.52M | -26.27M | -20.55M | -16.48M | -13.07M | -7.58M |
Balance Sheet | ||||||
| Total Assets | 158.62M | 143.43M | 133.23M | 123.19M | 111.62M | 91.69M |
| Cash, Cash Equivalents and Short-Term Investments | 11.38M | 319.00K | 15.50M | 22.03M | 32.04M | 28.84M |
| Total Debt | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K | 800.00K |
| Total Liabilities | 9.91M | 21.47M | 9.40M | 9.33M | 6.09M | 3.22M |
| Stockholders Equity | 148.71M | 121.96M | 123.82M | 113.86M | 105.53M | 88.47M |
Cash Flow | ||||||
| Free Cash Flow | -43.39M | -39.58M | -37.05M | -34.82M | -26.95M | -27.14M |
| Operating Cash Flow | -23.92M | -13.03M | -20.27M | -15.21M | -10.31M | -9.82M |
| Investing Cash Flow | -25.47M | -26.55M | -16.78M | -19.60M | -16.63M | -17.32M |
| Financing Cash Flow | 57.18M | 24.41M | 30.52M | 24.80M | 30.15M | 0.00 |
Alzinova AB Technical Analysis
Positive
0.82
Price Trends
0.47
Positive
0.57
Negative
0.93
Negative
Market Momentum
0.01
Negative
64.51
Neutral
65.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZ, the sentiment is Positive. The current price of 0.82 is above the 20-day moving average (MA) of 0.48, above the 50-day MA of 0.47, and below the 200-day MA of 0.93, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 64.51 is Neutral, neither overbought nor oversold. The STOCH value of 65.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ALZ.
Alzinova AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | kr162.41M | 1.83 | -294.38% | ― | 57.22% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr45.37M | -1.74 | -457.91% | ― | ― | -28.21% | |
49 Neutral | kr111.39M | -2.32 | -52.45% | ― | 7.80% | 42.81% | |
48 Neutral | kr84.45M | -2.10 | -21.31% | ― | -100.00% | 11.65% | |
47 Neutral | kr101.08M | -0.98 | -72.82% | ― | 55.24% | 70.00% | |
42 Neutral | kr17.61M | -0.43 | -120.13% | ― | ― | 24.27% |
* Healthcare Sector Average
SE:ALZ
Alzinova AB
0.55
-1.05
-65.89%
SE:BIOSGN
Biosergen AB
7.50
-37.20
-83.22%
SE:NICA
Nanologica AB
0.49
-0.66
-57.01%
SE:BIOVIC.B
Biovica International AB Class B
0.35
-0.41
-54.07%
SE:MODTX
Modus Therapeutics Holding AB
0.37
-0.10
-21.14%
SE:NXTCL
NextCell Pharma AB
1.00
>-0.01
-0.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.